The disclosure relates to treating and diagnosing telomere diseases, and methods of screening agents for treating and diagnosing telomere diseases.

The disclosure relates to treating and diagnosing telomere diseases, and methods of screening agents for treating and diagnosing telomere diseases.

Increased PARN as an indicator of a cancer involving loss or reduction in p53 function. PARN is also provided as a therapeutic target for treating a cancer involving loss or reduction in p53 function. Methods of treating a subject having a cancer involving loss or reduction in p53 function based on the level of PARN in a test sample obtained from the subject and administering an effective amount of a PARN inhibitor, alone or in conjunction with another chemotherapeutic agent, to the subject to treat the cancer.

The disclosure relates to treating and diagnosing telomere diseases, and methods of screening agents for treating and diagnosing telomere diseases.

The instant disclosure provides engineered proteins, constructs for expressing the engineered proteins, and methods of using the engineered proteins and constructs for tethering a protein of interest to an RNA molecule.